Stoke Therapeutics (STOK) Competitors $11.48 -0.07 (-0.56%) Closing price 07/3/2025 03:52 PM EasternExtended Trading$11.48 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock STOK vs. MIRM, AMRX, IBRX, XENE, BHC, GMTX, APLS, ARWR, TWST, and VCELShould you be buying Stoke Therapeutics stock or one of its competitors? The main competitors of Stoke Therapeutics include Mirum Pharmaceuticals (MIRM), Amneal Pharmaceuticals (AMRX), ImmunityBio (IBRX), Xenon Pharmaceuticals (XENE), Bausch Health Cos (BHC), Gemini Therapeutics (GMTX), Apellis Pharmaceuticals (APLS), Arrowhead Pharmaceuticals (ARWR), Twist Bioscience (TWST), and Vericel (VCEL). These companies are all part of the "pharmaceutical products" industry. Stoke Therapeutics vs. Its Competitors Mirum Pharmaceuticals Amneal Pharmaceuticals ImmunityBio Xenon Pharmaceuticals Bausch Health Cos Gemini Therapeutics Apellis Pharmaceuticals Arrowhead Pharmaceuticals Twist Bioscience Vericel Mirum Pharmaceuticals (NASDAQ:MIRM) and Stoke Therapeutics (NASDAQ:STOK) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends. Which has more volatility and risk, MIRM or STOK? Mirum Pharmaceuticals has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Is MIRM or STOK more profitable? Stoke Therapeutics has a net margin of 26.33% compared to Mirum Pharmaceuticals' net margin of -20.39%. Stoke Therapeutics' return on equity of 19.08% beat Mirum Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Mirum Pharmaceuticals-20.39% -33.63% -11.50% Stoke Therapeutics 26.33%19.08%15.72% Which has preferable earnings & valuation, MIRM or STOK? Mirum Pharmaceuticals has higher revenue and earnings than Stoke Therapeutics. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMirum Pharmaceuticals$336.89M7.34-$87.94M-$1.61-31.01Stoke Therapeutics$36.56M17.15-$88.98M$0.7914.54 Does the media prefer MIRM or STOK? In the previous week, Stoke Therapeutics had 3 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 11 mentions for Stoke Therapeutics and 8 mentions for Mirum Pharmaceuticals. Stoke Therapeutics' average media sentiment score of 0.18 beat Mirum Pharmaceuticals' score of 0.17 indicating that Stoke Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Stoke Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate MIRM or STOK? Mirum Pharmaceuticals currently has a consensus target price of $65.50, suggesting a potential upside of 31.18%. Stoke Therapeutics has a consensus target price of $23.20, suggesting a potential upside of 102.00%. Given Stoke Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Stoke Therapeutics is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Stoke Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 SummaryStoke Therapeutics beats Mirum Pharmaceuticals on 12 of the 15 factors compared between the two stocks. Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STOK vs. The Competition Export to ExcelMetricStoke TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$627.08M$2.89B$5.49B$9.01BDividend YieldN/A2.43%5.38%4.09%P/E Ratio14.5421.5627.4220.26Price / Sales17.15245.52407.97121.21Price / CashN/A41.9536.6357.47Price / Book2.667.518.085.67Net Income-$88.98M-$55.05M$3.16B$248.47M7 Day Performance-1.25%4.59%2.81%3.29%1 Month Performance4.98%4.86%3.68%5.19%1 Year Performance-9.35%5.82%35.29%21.35% Stoke Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STOKStoke Therapeutics4.0457 of 5 stars$11.49-0.6%$23.20+102.0%-9.4%$627.08M$36.56M14.54100Analyst ForecastMIRMMirum Pharmaceuticals3.7125 of 5 stars$50.28-0.1%$65.50+30.3%+47.4%$2.49B$336.89M-31.23140News CoveragePositive NewsAMRXAmneal Pharmaceuticals3.2301 of 5 stars$7.91+1.2%$11.60+46.6%+26.8%$2.48B$2.79B-197.708,100IBRXImmunityBio1.8889 of 5 stars$2.76-3.8%$12.25+343.8%-57.0%$2.44B$14.74M-4.76590Negative NewsGap UpXENEXenon Pharmaceuticals3.2015 of 5 stars$31.49-1.7%$54.82+74.1%-3.9%$2.42B$9.43M-9.75210BHCBausch Health Cos3.1657 of 5 stars$6.11-1.1%$7.42+21.4%-2.8%$2.26B$9.73B-55.5520,700GMTXGemini TherapeuticsN/A$51.61+3.0%N/A+27.8%$2.24BN/A-51.6130High Trading VolumeAPLSApellis Pharmaceuticals4.4471 of 5 stars$17.62-0.4%$40.05+127.3%-49.2%$2.21B$775.84M-9.84770Trending NewsAnalyst ForecastAnalyst RevisionARWRArrowhead Pharmaceuticals3.9373 of 5 stars$15.51+1.2%$43.71+181.8%-33.1%$2.14B$3.55M-11.08400Positive NewsTWSTTwist Bioscience4.4841 of 5 stars$35.33+2.0%$50.40+42.7%-20.6%$2.12B$347.68M-10.87990Positive NewsVCELVericel2.9292 of 5 stars$41.80-0.5%$61.14+46.3%-7.0%$2.10B$237.22M1,393.80300Positive News Related Companies and Tools Related Companies MIRM Alternatives AMRX Alternatives IBRX Alternatives XENE Alternatives BHC Alternatives GMTX Alternatives APLS Alternatives ARWR Alternatives TWST Alternatives VCEL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STOK) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
